KFA Private Wealth Group LLC Buys 96 Shares of Amgen Inc. (NASDAQ:AMGN)

KFA Private Wealth Group LLC increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 7.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,428 shares of the medical research company’s stock after buying an additional 96 shares during the quarter. KFA Private Wealth Group LLC’s holdings in Amgen were worth $411,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Briaud Financial Planning Inc acquired a new stake in Amgen during the 3rd quarter valued at $26,000. BOK Financial Private Wealth Inc. acquired a new stake in Amgen during the 4th quarter valued at $29,000. OFI Invest Asset Management acquired a new stake in Amgen during the 3rd quarter valued at $26,000. Planned Solutions Inc. acquired a new stake in Amgen during the 4th quarter valued at $30,000. Finally, Providence Capital Advisors LLC acquired a new stake in Amgen during the 3rd quarter valued at $30,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 0.2 %

AMGN traded up $0.60 on Friday, hitting $269.98. 2,436,947 shares of the company were exchanged, compared to its average volume of 2,822,655. Amgen Inc. has a 12 month low of $211.71 and a 12 month high of $329.72. The company has a market cap of $144.81 billion, a PE ratio of 21.62, a PEG ratio of 2.54 and a beta of 0.58. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The stock’s fifty day moving average is $275.10 and its 200-day moving average is $281.45.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating the consensus estimate of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter in the prior year, the business earned $4.09 earnings per share. The firm’s revenue for the quarter was up 19.8% on a year-over-year basis. Equities research analysts predict that Amgen Inc. will post 19.43 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 3.33%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 72.06%.

Wall Street Analyst Weigh In

AMGN has been the subject of several research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $329.00 target price on shares of Amgen in a research note on Wednesday, April 3rd. TD Cowen lowered their target price on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research note on Wednesday, April 17th. StockNews.com cut Amgen from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. Oppenheimer reissued an “outperform” rating and issued a $350.00 target price on shares of Amgen in a research note on Thursday, February 1st. Finally, UBS Group lowered their target price on Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Ten analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $296.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.